Canadian Digestive Health Foundation Public Impact Series. Inflammatory Bowel Disease in Canada: Incidence, Prevalence, and Direct and Indirect Economic Impact-Reference-Cited by-同舟云学术

Canadian Digestive Health Foundation Public Impact Series. Inflammatory Bowel Disease in Canada: Incidence, Prevalence, and Direct and Indirect Economic Impact

Published:2010 Issue:11 Volume:24 Page:651-655
ISSN:0835-7900
Container-title:Canadian Journal of Gastroenterology
language:en
Short-container-title:Canadian Journal of Gastroenterology

Author:

Fedorak Richard N¹,Wong Karen¹,Bridges Ron²

Affiliation:

1. Division of Gastroenterology, University of Alberta, Edmonton, Canada

2. Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada

Abstract

The Canadian Digestive Health Foundation initiated a scientific program to assess the incidence, prevalence, mortality and economic impact of digestive disorders across Canada in 2009. The current article presents the updated findings from the study concerning inflammatory bowel diseases – specifically, Crohn’s disease and ulcerative colitis.

Publisher

Hindawi Limited

Subject

Gastroenterology,General Medicine

Link

http://downloads.hindawi.com/journals/cjgh/2010/407095.pdf

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Biomarkers for Inflammatory Bowel Disease and Colorectal Cancer: An Interplay between Metabolic Dysregulation and Excessive Inflammation;International Journal of Molecular Sciences;2023-03-22

2. Inflammatory bowel disease patient perceptions of diagnostic and monitoring tests and procedures;BMC Gastroenterology;2019-02-13

3. Characterization of Serotonin Signaling Components in Patients with Inflammatory Bowel Disease;Journal of the Canadian Association of Gastroenterology;2018-08-10

4. The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases;Canadian Journal of Gastroenterology and Hepatology;2018

5. Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation;Journal of Medical Economics;2017-09-01